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Abstract
Background: Glycosylation is one of the major posttranslational modifications of proteins and it is essential for
proteins to obtain normal biological functions. Congenital disorders of glycosylation (CDGs) are very rare genetic
disorders that lack enzymes needed for glycosylation. Phosphomannomutase-2 (PMM2)-CDG is the most common
type of CDG. CDGs can cause a wide variety of clinical symptoms in almost every organ system. Muscular
hypotonia is often present in patients with CDGs and is one of the most notable problems for anesthetic
management because the susceptibility to nondepolarizing neuromuscular blocking agents (NMBAs) in patients
with CDGs is unknown.
Case presentation: The patient was a 17-month-old boy who weighed 6.5 kg and was 71 cm tall. He presented
for strabismus surgery. He had muscular hypotonia, mental retardation, hepatic dysfunction, mild cerebellar
hypoplasia, and some dysmorphic features including inverted nipples and abnormal subcutaneous fat distribution
of the hips. Gene analysis revealed a compound heterozygous mutation in the gene encoding PMM2 and the
patient was diagnosed as having PMM2-CDG. General anesthesia was performed with sevoflurane, nitrous oxide,
and rocuronium. Neuromuscular monitoring was performed during anesthesia using train-of-four (TOF)-Watch®
(MSD, Japan). As postoperative analgesia, the surgeon performed sub-Tenon’s anesthesia. We did not use any
intravenous analgesic. After completion of the operation, residual rocuronium was competed by administration of
sugammadex. The patient gained consciousness and spontaneous breathing was established shortly thereafter, and
the trachea was smoothly extubated. He was transported to an inpatient ward and was discharged to his home the
next day without any complication.
Conclusions: We performed safe anesthetic management in a 17-month-old boy with PMM2-CDG using
rocuronium under neuromuscular monitoring.
A patient with PMM2-CDG may show nearly normal susceptibility to nondepolarizing NMBAs.
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Background
Glycosylation is one of the major posttranslational modi-
fications of proteins and it is essential for proteins to
obtain normal biological functions. Congenital disorders
of glycosylation (CDGs) are very rare genetic disorders
caused by genetic deficits of some of the enzymes that
are essential for glycosylation. Phosphomannomutase-2
(PMM2) converts mannose-6-phosphate into mannose-
1-phosphate. PMM2-CDG, caused by PMM2 deficiency,
is the most common type of CDG [1]. Although only
about 700 patients with PMM2-CDG have been reported
in the world [1], there may be many undiagnosed or
misdiagnosed patients with CDG because of the lack of
recognition of these disorders.
Glycosylation occurs in every living cell, and hence,
CDG can cause abnormalities in nearly every organ sys-
tem including mental retardation, hypertrophic cardiomy-
opathy, epilepsy, muscular hypotonia, hepatic dysfunction,
coagulopathy, and endocrinopathy [1]. There is a high
childhood mortality rate of approximately 25% in PMM2-
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CDG patients due to severe infection or organ failure [2].
We herein report anesthetic management of a PMM2-
CDG pediatric patient with muscular hypotonia and
hepatic dysfunction. Muscular hypotonia is one of the
most notable problems for general anesthesia because
neuromuscular blocking agents (NMBAs) can have an
unexpectedly prolonged effect in patients with hypo-
tonia. Since there have been very few reports about
anesthetic management of patients with CDG [3, 4], the
susceptibility of patients with CDG to nondepolarizing
NMBAs remains unclear. This is the first case report about
anesthetic management of a patient with PMM2-CDG
using rocuronium under neuromuscular monitoring.
Case presentation
The patient was a 17-month-old boy who weighed 6.5 kg
and was 71 cm tall. He presented for strabismus surgery.
He had muscular hypotonia, mental retardation, hepatic
dysfunction, mild cerebellar hypoplasia, and some dys-
morphic features including inverted nipples and abnormal
subcutaneous fat distribution of the hips. He could move
his extremities and head weakly, but he could not roll over
and hold his head up. Although the patient had a sucking
disorder due to muscular hypotonia, it was relatively mild
and he did not need a tube for feeding. There was no pre-
operative history of aspiration pneumonia or sleep apnea
at home. He was being administered ursodeoxycholic acid
orally for treatment of his hepatic dysfunction.
Gene analysis revealed a compound heterozygous muta-
tion in the gene encoding PMM2, and the patient was
diagnosed as having PMM2-CDG. A preoperative labora-
tory examination revealed elevated transaminases (alanine
aminotransferase and aspartate aminotransferase levels of
302 and 387 U/L, respectively).
After arrival in the operating room, an electrocardio-
gram and pulse oximeter were set up and general
anesthesia was induced with a mixture of 5% sevoflur-
ane, 50% nitrous oxide, and 50% oxygen. A 24-G intra-
venous line was inserted into a vein of the back of his
hand. Neuromuscular monitoring was performed during
anesthesia using train-of-four (TOF)-Watch® (MSD,
Japan) by stimulating the ulnar nerve of the forearm and
sensing at the thumb. After calibration of TOF-Watch®,
2 mg (0.3 mg/kg) of rocuronium was first administered
and TOF count 2 min later was 1/4. Then, 1 mg of
rocuronium (total dose of 0.46 mg/kg) was added and
TOF count 1 min later was 0/4. The trachea was intu-
bated with a cuffed endotracheal tube. General
anesthesia was maintained with a mixture of 1–3% of
sevoflurane, 50% of nitrous oxide, and 50% of oxygen.
After administration of rocuronium, TOF count was
measured every 10 min during anesthesia. TOF counts
10 to 30 min later were all 0/4. Forty minutes later, TOF
count had reached 2/4 and TOF ratios were 32, 80, and
89% at 50, 60, and 70 min later, respectively. The
surgeon performed sub-Tenon’s anesthesia with 1% of
lidocaine for postoperative analgesia. General circulatory
and respiratory conditions were stable during surgery.
After completion of the operation, administration of
sevoflurane and nitrous oxide was discontinued and the
patient was ventilated with 100% of oxygen followed by
administration of 7 mg (1 mg/kg) of sugammadex. The
patient gained consciousness and spontaneous breathing
was established shortly thereafter, and the trachea was
smoothly extubated. He was transported to an inpatient
ward and was discharged to his home the next day with-
out any clinical symptoms of respiratory complications
including aspiration pneumonia or upper airway obstruc-
tion and worsening hepatic function including jaundice.
There was no perioperative bleeding complication.
Discussion
We experienced a case of general anesthesia in a
PMM2-CDG patient with hypotonia. In addition to the
usual considerations for general anesthesia in pediatric
patients, we paid careful attention to the use of NMBAs
under neuromuscular monitoring and safely managed
the patient with no complications. We also needed to
take special care for selecting anesthetics because the
patient had hepatic dysfunction.
Our case indicates that a patient with PMM2-CDG may
show nearly normal susceptibility to nondepolarizing
NMBAs. In general, NMBAs should be used very carefully
in patients with muscular hypotonia. In patients with
CDG, it is known that the expression of postsynaptic
acetylcholine receptor with normal function is reduced
[5]. In addition, both type 1 and type 2 muscle fibers are
hypotrophic and the normal pattern of myofibrillar array
is lost [6]. These functional and morphological changes in
postsynapses and muscle fibers cause hypotonia in pa-
tients with CDG. We administered a requisite minimum
dose of rocuronium using neuromuscular monitoring.
According to a previous report [7], the mean recovery
times from 0.45 mg/kg of rocuronium during isoflurane
anesthesia in infants aged 5 to 12 months measured as
TOF ratio >70% was 43.7 (range: 33.8–72.0) minutes.
According to another report [8], the mean recovery times
from 0.3 to 0.6 mg/kg of rocuronium during sevoflurane
anesthesia in children aged 2 to 7 years measured as TOF
ratio >80% were 24 (±8) (range 9–45) and 50 (±22) (range
24–122) minutes. The recovery time from 0.46 mg/kg of
rocuronium in our patient, aged 17 months, measured as
TOF ratio >80% was between 50 and 60 min and seems to
be consistent with those reports. Although the level of
muscular relaxation was not checked continuously, the
approximate recovery time in this case provides important
information because there is no previous report about
recovery time.
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Hepatic dysfunction is also a common feature in CDG
patients [1]. A previous study revealed that swollen hepa-
tocytes and fibrosis were present in liver specimens of
patients with PMM2-CDG [9]. We considered the use of
neuromuscular monitoring during anesthesia to be abso-
lutely necessary for CDG patients because rocuronium is
eliminated from plasma mainly by hepatic intake and
biliary excretion [10, 11]. Since hepatic dysfunction could
alter the metabolism of various other medications associ-
ated with anesthetic management, including intravenous
anesthetics, opioids, and acetaminophen, we needed to
pay special care to the selection of medications. Nitrous
oxide and sevoflurane were administered for induction
and maintenance of general anesthesia, and a local
anesthetic agent was chosen for postoperative analgesia
with avoidance of opioids in this case. Long-acting opioids
should be avoided or very carefully used in patients with
hepatic dysfunction because the effect could be abnor-
mally prolonged. They may also cause serious respiratory
complications in patients with muscular hypotonia be-
cause respiratory depression induced by opioids and
respiratory muscular hypotonia may work synergistically
in the postoperative period. In more invasive surgeries,
remifentanil may be useful for intraoperative analgesia [3].
Acetaminophen was also avoided in this case because of
the fear of further deterioration of hepatic function caused
by hepatotoxicity by acetaminophen.
It is generally considered that some respiratory com-
plications including aspiration pneumonia and upper
airway obstruction can occur during the perioperative
period [12, 13]. Although there was no preoperative
history of frequent regurgitation, aspiration pneumonia,
or sleep apnea at home, the patient had a mild sucking
disorder and hypotonia. Therefore, we considered that
he had a mild risk of perioperative respiratory complica-
tions. We performed careful anesthetic management
with the minimum dose of a NMBA under neuromuscu-
lar monitoring and no usage of opiates, and we safely
managed the patient without any complications.
Conclusions
We describe a case in which we safely performed general
anesthesia in a patient with PMM2-CDG using rocuro-
nium with neuromuscular monitoring. Our case indi-
cates that a patient with PMM2-CDG may show nearly
normal susceptibility to nondepolarizing NMBAs. Fur-
ther study is needed for a better understanding of and
management of patients with CDG.
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